TARGETED THERAPIES Afatinib-new therapy option for EGFR-mutant lung cancer

被引：82

作者：

Yu, Helena A. ^{[1
]}

Pao, William ^{[2
]}

机构：

[1] Weill Cornell Med Coll, Mem Sloan Kettering Canc Ctr, Dept Med, Thorac Oncol Serv,Div Solid Tumor Oncol, New York, NY 10065 USA

[2] Vanderbilt Ingram Canc Ctr, Div Hematol Oncol, Nashville, TN 37212 USA

来源：

NATURE REVIEWS CLINICAL ONCOLOGY | 2013年 / 10卷 / 10期

关键词：

1ST-LINE TREATMENT; OPEN-LABEL; ERLOTINIB; CHEMOTHERAPY; MULTICENTER; PHASE-3; TRIAL;

D O I：

10.1038/nrclinonc.2013.154

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

On 15 July 2013, the FDA approved afatinib as a first-line treatment for patients with metastatic non-small-cell lung cancer whose tumours harbour exon 19 deletions or exon 21 (L858R) EGFR substitution mutations. We discuss three recent studies investigating afatinib in this molecular subset of patients.

引用

页码：551 / 552

页数：2

共 50 条

[1] Optimizing the Sequence of Anti-EGFR-Targeted Therapy in EGFR-Mutant Lung Cancer
Meador, Catherine B.
Jin, Hailing
de Stanchina, Elisa
Nebhan, Caroline A.
Pirazzoli, Valentina
Wang, Lu
Lu, Pengcheng
Vuong, Huy
Hutchinson, Katherine E.
Jia, Peilin
Chen, Xi
Eisenberg, Rosana
Ladanyi, Marc
Politi, Katerina
Zhao, Zhongming
Lovly, Christine M.
Cross, Darren A. E.
Pao, William
MOLECULAR CANCER THERAPEUTICS, 2015, 14 (02) : 542 - 552
[2] Does neoadjuvant targeted therapy provide an opportunity for resectable EGFR-mutant lung cancer: a real-world retrospective study
Lv, Chao
Ma, Yuanyuan
Feng, Qin
Lu, Fangliang
Chi, Yongkun
Wu, Nan
Fang, Jian
Yang, Yue
JOURNAL OF THORACIC DISEASE, 2020, 12 (10) : 5324 - +
[3] Activity of erlotinib when dosed below the maximum tolerated dose for EGFR-mutant lung cancer: Implications for targeted therapy development
Lampson, Benjamin L.
Nishino, Mizuki
Dahlberg, Suzanne E.
Paul, Danie
Santos, Abigail A.
Jaenne, Pasi A.
Oxnard, Geoffrey R.
CANCER, 2016, 122 (22) : 3456 - 3463
[4] How to develop novel treatments for EGFR-mutant lung cancer
Banna, Giuseppe Luigi
Tiseo, Marcello
FUTURE ONCOLOGY, 2015, 11 (17) : 2375 - 2378
[5] Reduced chemotherapy sensitivity in EGFR-mutant lung cancer patient with frontline EGFR tyrosine kinase inhibitor
Zeng, Zhu
Yan, Hong-hong
Zhang, Xu-chao
Zhong, Wen-zhao
He, Yan-yan
Guan, Jin-lin
Niu, Fei-yu
Xie, Zhi
Huang, Yi-sheng
Xu, Chong-rui
Dong, Song
Wu, Yi-long
LUNG CANCER, 2014, 86 (02) : 219 - 224
[6] Expression of EGFR-mutant proteins and genomic evolution in EGFR-mutant transformed small cell lung cancer
Zhang, Shi-Ling
Zhang, Chan -Yuan
Chen, Yu-Qing
Li, Yu -Fa
Xie, Zhi
Zhang, Xu-Chao
Zhou, Qing
Zhong, Wen-Zhao
Huang, Jie
Sun, Hao
Zheng, Ming-Ying
Xiao, Fa-Man
Yan, Hong-Hong
Lu, Dan-Xia
Lv, Zhi-Yi
Wu, Yi-Long
Chen, Hua-Jun
Yang, Jin-Ji
JOURNAL OF THORACIC DISEASE, 2023, 15 (09) : 4620 - 4635
[7] Features of tumor-microenvironment images predict targeted therapy survival benefit in patients with EGFR-mutant lung cancer
Wang, Shidan
Rong, Ruichen
Yang, Donghan M.
Fujimoto, Junya
Bishop, Justin A.
Yan, Shirley
Cai, Ling
Behrens, Carmen
Berry, Lynne D.
Wilhelm, Clare
Aisner, Dara
Sholl, Lynette
Johnson, Bruce E.
Kwiatkowski, David J.
Wistuba, Ignacio I.
Bunn, Paul A.
Minna, John
Xiao, Guanghu
Kris, Mark G.
Xie, Yang
JOURNAL OF CLINICAL INVESTIGATION, 2023, 133 (02)
[8] Overcoming therapy resistance in EGFR-mutant lung cancer
Passaro, Antonio
Janne, Pasi A.
Mok, Tony
Peters, Solange
NATURE CANCER, 2021, 2 (04) : 377 - 391
[9] Osimertinib for EGFR-mutant non-small cell lung cancer: place in therapy and future perspectives
Ricciuti, Biagio
JOURNAL OF THORACIC DISEASE, 2019, 11 : S249 - S252
[10] Combination of afatinib with cetuximab in patients with EGFR-mutant non-small-cell lung cancer resistant to EGFR inhibitors
Gomes, Jessica Ribeiro
Cruz, Marcelo Rocha S.
ONCOTARGETS AND THERAPY, 2015, 8 : 1137 - 1142

← 1 2 3 4 5 →